Article and Video CATEGORIES

Cancer Journey

Search By

Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks
gracevideo

Please Note: New Treatments Have Emerged Since this Original Post
Author
GRACE Videos and Articles

ASCO 2015 Highlights 07

 

A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.

[powerpress]

Download Transcript

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Next Previous link

Previous PostNext Post

Related Content

Recent Comments

JOIN THE CONVERSATION
ROS 1
By JanineT GRACE … on
Hi siigs, I'm sorry you're…
By JanineT GRACE … on
Tomorrow Saturday, Oct. 25, 2025
By JanineT GRACE … on
Blood Cancers OncTalk-Live, Free, Learn Sat. Oct. 25
By JanineT GRACE … on